BCL2 and B-cell chronic lymphocytic leukemia: The effects we observed of ONC‐212 on PI3‐kinase and MAPK‐ERK1/2 signaling and on the BCL2 family of proteins are consistent with previous studies of ONC‐201 [39] and raise the possibility that the drug may be effective for CLL patients with ibrutinib or venetoclax resistant disease or may reduce the risk of disease evolution and development of drug resistant clones.